Ethoximod Crystal Forms for Controlled Dissolution Performance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing preparations of ethoximod do not account for the impact of mixed crystal forms on dissolution performance and efficacy, which is crucial for pharmaceutical development and treatment effectiveness.
Innovation Solution
Development of specific crystal forms of ethoximod, namely crystal form A and crystal form B, through controlled preparation methods, including solvent evaporation and spray drying, to enhance stability, solubility, and mechanical properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional preparation methods are used without controlling crystal forms, then the preparation process is simple, but the dissolution performance and efficacy are significantly impacted
Solution Approach 1:
The patent applies parameter changes by controlling crystallization conditions including solvent selection (methanol, water, acetone, ethyl acetate, toluene, or their mixtures), temperature parameters (heating to dissolve followed by cooling to crystallize), and evaporation rate parameters to obtain specific crystal forms with improved dissolution performance and efficacy while maintaining a feasible preparation process
Solution Approach 2:
The patent utilizes phase transitions by controlling the crystallization process from solution phase to solid crystal phase through controlled cooling and evaporation, obtaining distinct crystal forms (Crystal Form A, B, C, or D) with different properties that directly impact dissolution performance and therapeutic efficacy
2Productivity
If crystal forms are not controlled in preparation, then the manufacturing process is straightforward, but the drug efficacy is compromised
Solution Approach 1:
The patent implements parameter changes by optimizing crystallization conditions including solvent composition, temperature profiles, and evaporation rates to produce crystal forms with enhanced efficacy while maintaining high manufacturing efficiency through a streamlined process that doesn't require complex additional steps
3Ease of manufacture
If mixed crystal forms are present in preparation, then no additional control measures are needed, but dissolution performance and efficacy are significantly impacted
Solution Approach 1:
The patent applies parameter changes by controlling crystallization parameters including solvent selection, temperature, and evaporation rate to obtain consistent, pure crystal forms (A, B, C, or D) without requiring complex additional purification steps, thus maintaining ease of manufacture while achieving high crystal form consistency
Solution Approach 2:
The patent implements preliminary action by establishing controlled crystallization conditions from the outset of the preparation process, preventing the formation of mixed crystal forms before they occur, thereby ensuring consistent crystal form without requiring subsequent separation or purification operations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystal forms A and B exhibit improved stability, solubility, and mechanical properties, making them suitable for pharmaceutical industrialization with lower hygroscopicity and better compressibility, thus enhancing drug development prospects.
Implementation Method 1
adding a sample of ethoximod to methanol, heating to dissolve the sample of ethoximod
Implementation Method 2
evaporating a solvent to obtain the crystal form A
Implementation Method 3
adding a crystal form A of ethoximod to a mixed solvent to dissolve the crystal form A of ethoximod until a clear solution is obtained
Implementation Method 4
spray drying the solution to obtain the crystal form B of ethoximod
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
Provided in the present application are crystal forms of ethoximod, a preparation method therefor and the use thereof. The crystal forms involve a crystal form A and a crystal form B, and the crystal form A and the crystal form B can stably exist, have low hygroscopicity, high solubility, good mechanical stability, low fluidity, relatively low adhesiveness and good compressibility, and thus have medical industrial prospects.